9 completed, 3 terminated, 2 withdrawn. 14 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 14 | Completed 9, Terminated 3, Withdrawn 2 |
Follow Acute Myelogenous Leukemia: new trials by email Literature Review of Acute Myelogenous Leukemia trials Research Report on Acute Myelogenous Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| LILRB4 STAR-T Cell Therapy for Monocytic Leukemia LILRB4 STAR-T cells injection - Acute Myelogenous Leukemia, Chronic Myelomonocytic Leukemia | Not applicable | Completed | Institute of Hematology & Blood Diseases Hospital, China | 1 | 2023-02-16 | 2026-02-11 |
| Diagnosis and Treatment of Periodontal Disease in Patients With AML Scaling and Root Planing - AML, Acute Myelogenous Leukemia | Not applicable | Withdrawn | Masonic Cancer Center, University of Minnesota | 2022-05-01 | 2023-02-22 | |
| CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for AML Patients Not in CR Interventions - Acute Myelogenous Leukemia | Not applicable | Terminated | Miltenyi Biotec B.V. & Co. KG | 1 | 2017-10-18 | 2020-07-09 |
| iCare for Cancer Patients Molecular diagnostic testing - Myelodysplastic Syndromes, Acute Myeloid Leukemia | Not applicable | Terminated | University of Florida | 136 | 2015-06-26 | 2019-12-20 |
| Selecting a Favorable KIR Donor in Unrelated HCT for AML KIR genotype - Acute Myelogenous Leukemia | Not applicable | Completed | Masonic Cancer Center, University of Minnesota | 506 | 2011-06-01 | 2021-03-11 |
| Investigating the Relationship Between Physical Function, Comorbidity and Cytogenetic Risk Group in Older Adults With Acute Myelogenous Leukemia (AML) Bedside assessment - ACUTE MYELOGENOUS LEUKEMIA | Not applicable | Completed | Wake Forest University Health Sciences | 82 | 2009-01-01 | 2023-04-10 |
| Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia Umbilical Cord Blood Transfusion, Fludarabine, Busulfan - Leukemia, Myelodysplasia | Not applicable | Completed | University of Miami | 2 | 2008-08-01 | 2015-12-28 |
| Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR Tetanus - Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia | Not applicable | Completed | Robert Krance | 7 | 2008-03-01 | 2020-04-21 |
| In-Vivo Activated T-Cell Depletion to Prevent GVHD Cyclophosphamide, Fludarabine, Cyclosporine - Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | Not applicable | Terminated | Indiana University | 10 | 2007-10-01 | 2014-10-06 |
| The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients Food Safety Guidelines, Neutropenic Diet - Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia | Not applicable | Completed | Indiana University | 149 | 2007-09-01 | 2017-02-08 |
| Unrelated Donor Stem Cell Transplantation Allogeneic transplantation - Severe Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria | Not applicable | Completed | Scripps Health | 64 | 2005-03-01 | 2022-11-23 |
| Low Dose Melphalan and Bortezomib for AML and High-Risk MDS Melphalan, Bortezomib, Melphalan and bortezomib - Acute Myelogenous Leukemia, Myelodysplastic Syndromes | Not applicable | Completed | Dartmouth-Hitchcock Medical Center | 26 | 2004-09-01 | 2018-10-24 |
| Nonmyeloablative Allogeneic Transplant Nonmyeloablative Allogeneic Transplant - Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria | Not applicable | Completed | Scripps Health | 36 | 2001-10-01 | 2022-11-23 |
| Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes Dendritic Cell Activated Lymphocyte - Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia | Not applicable | Withdrawn | M.D. Anderson Cancer Center | 2001-01-31 | 2018-10-25 |
Leukemia, Myeloid, Acute (14) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (7) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (5) · Lymphoma, Non-Hodgkin (5) · Myelodysplastic Syndromes (5) · Hodgkin Disease (4) · Multiple Myeloma (4) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Anemia, Aplastic (2) · Anemia, Refractory, with Excess of Blasts (2) · Hemoglobinuria, Paroxysmal (2) · Lymphoma, Mantle-Cell (2) · Primary Myelofibrosis (2) · Sarcoma (2) · Breast Neoplasms (1)
Hematologic Diseases (14) · Hemic and Lymphatic Diseases (14) · Leukemia, Myeloid (14) · Neoplasms by Histologic Type (14) · Leukemia (13) · Neoplasms (13) · Bone Marrow Diseases (9) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Leukemia, Lymphoid (7) · Lymphatic Diseases (7) · Lymphoproliferative Disorders (7) · Chronic Disease (6) · Disease Attributes (6) · Pathologic Processes (6)
Melphalan (2) · fludarabine (2) · Basiliximab (1) · Bortezomib (1) · Busulfan (1) · Cyclophosphamide (1) · Cyclosporine (1) · Methods (1) · Molecular Diagnostic Techniques (1) · Mycophenolic Acid (1) · Root Planing (1) · Tetanus Toxoid (1) · Tooth Exfoliation (1) · Transplantation, Homologous (1) · fludarabine phosphate (1)
Indiana University (2) · Masonic Cancer Center, University of Minnesota (2) · Scripps Health (2) · Dartmouth-Hitchcock Medical Center (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · M.D. Anderson Cancer Center (1) · Miltenyi Biotec B.V. & Co. KG (1) · Robert Krance (1) · University of Florida (1) · University of Miami (1) · Wake Forest University Health Sciences (1)
United States (10) · China (1)
Armin Rashidi, MD, PhD (1) · Christopher R. Cogle, MD (1) · Daniel Weisdorf, M.D. (1) · Heidi Klepin, MD (1) · Jeffrey Bubis, DO (1) · Jeffrey W. Andrey, M.D. (1) · Jeffrey W. Andrey, MD (1) · Jianxiang Wang (1) · Karen Moody, MD, MS (1) · Marc Gautier, MD (1) · Martin Andreasky, MD, PhD (1) · Richard Champlin, MD,BS (1) · Robert Krance, MD (1) · Robert Nelson, MD (1)
P01CA111412 (1)